VERTEX PHARMACEUTICALS INC / MA Research And Development Expense

Quick Answer

VERTEX PHARMACEUTICALS INC / MA reported Research And Development Expense of $3.05 billion for the year ending 2021.

  • VERTEX PHARMACEUTICALS INC / MA showed an increase of +66.8% in Research And Development Expense from 2020 to 2021.
  • This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 9, 2022.
  • XBRL data for this metric is available from 2008 to 2021 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q3 2011: $189.05 million | Q4 2011: $186.44 million | Q1 2012: $196.37 million | Q2 2012: $196.54 million | Q3 2012: $200.16 million | Q4 2012: $213.11 million | Q1 2013: $210.20 million | Q2 2013: $213.99 million | Q3 2013: $219.44 million | Q4 2013: $238.46 million | Q1 2014: $238.62 million | Q2 2014: $224.49 million | Q3 2014: $190.94 million | Q4 2014: $201.46 million | Q1 2015: $215.60 million | Q2 2015: $223.86 million | Q3 2015: $246.28 million | Q4 2015: $310.18 million | Q1 2016: $255.86 million | Q2 2016: $271.01 million | Q3 2016: $272.37 million | Q4 2016: $248.45 million | Q1 2017: $273.56 million | Q2 2017: $289.45 million | Q3 2017: $454.95 million | Q4 2017: $306.66 million | Q1 2018: $310.55 million | Q2 2018: $337.53 million | Q3 2018: $330.51 million | Q4 2018: $437.88 million | Q1 2019: $339.49 million | Q2 2019: $379.09 million | Q3 2019: $555.95 million | Q4 2019: $480.01 million | Q1 2020: $448.53 million | Q2 2020: $420.93 million | Q3 2020: $493.50 million | Q4 2020: $466.58 million | Q1 2021: $456.00 million | Q2 2021: $1.41 billion | Q3 2021: $493.75 million | Q1 2022: $603.10 million.
  • Over the full 14 years of available data (2008 to 2021), VERTEX PHARMACEUTICALS INC / MA's Research And Development Expense has grown by 490.3%.
  • Historical annual values: Fiscal year 2021: $3.05 billion | Fiscal year 2020: $1.83 billion | Fiscal year 2019: $1.75 billion | Fiscal year 2018: $1.42 billion | Fiscal year 2017: $1.32 billion | Fiscal year 2016: $1.05 billion | Fiscal year 2015: $995.92 million | Fiscal year 2014: $855.51 million | Fiscal year 2013: $882.10 million | Fiscal year 2012: $765.91 million | Fiscal year 2011: $707.71 million | Fiscal year 2010: $637.42 million | Fiscal year 2009: $550.27 million | Fiscal year 2008: $516.91 million.
  • Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: